A spine biologics company's $100 million investment deal and six more key updates in regenerative medicine in the last two months:
1. Pacira BioSciences signed an agreement to acquire Flexion Therapeutics. Flexion develops local non-opioid therapies for patients with musculoskeletal conditions, postsurgical pain and lower back pain. The transaction is expected to close in the fourth quarter.
2. Goldman Sachs listed DiscGenics CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021.
3. Medtronic will no longer distribute Aziyo Biologics' cellular bone matrix products. The decision comes after a single lot of Aziyo's FiberCel product was recalled in June.
4. Bioventus' acquisition of Misonix was completed Oct. 29.
5. Pacira Biosciences reported an uptick in total sales and its Exparel injectable analgesic during the third quarter. Read more details here.
6. The number of businesses and medical clinics advertising stem cell-based therapies has skyrocketed in the U.S. over the past five years, according to a study published in Cell Stem Cell.
7. Houston-based FibroBiologics, a regenerative medicine company developing treatments for chronic disease using fibroblast cells, signed an agreement with a private investment group that will provide the company with up to $100 million over the next three years.